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During thousands of years of clinical validation and practice, the efficacy and safety of
traditional Chinese medicine (TCM) have been widely recognized in the prevention and
treatment for various diseases. However, further toxicology research of TCM new drugs is
still necessary.
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NECESSITY OF TOXICOLOGY RESEARCH IN DRUG SAFETY
EVALUATION OF TCM
It is well known that many valuable safety information of TCM
comes directly from clinical use, which can be perceived as more
important reference for TCM safety evaluation, to some extent,
even than that from animals. However, the value of previously
obtained clinical information will be weakened for various rea-
sons in the development of novel drugs of TCM.
Firstly, the scale of patients treated by TCMs has changed from
individuals to populations. Generally, individualized medication
was historically used in TCM, with sporadic and individual
features. The scientific validity of conclusions from traditional
medicine experience is easily to be oppugned due to the indi-
viduation of clinical data in traditional medicine experience.
Therefore, the toxicology research is urgently needed to support
the safe and wide usage of TCM.
Secondly, the awareness of TCM safety has been restricted
by the development of subjects and science of that time. In the
history of the TCM practice, clinical toxicity observations were
based on the development of technology and science at that time.
In recent years, some new toxic ingredients and effects in TCM
have been recognized, such as the renal toxicity of aristolochic
acid in Caulis aristolochiae manshuriensis (Chen et al., 2006) and
the hepatotoxicity of monocrotaline in Gynura segetum (Lin et al.,
2011).
Thirdly, some factors may affect the ingredients of novel drugs
of TCM compared with that applied historically. Compared with
the previous clinical application, the changes of medicinal mate-
rial source, the prescription composition, extraction technology,
selected population, administration mode, dosage, excipients, can
lead to functional changes of drug ingredients, which may affect
the safety of novel drugs.
Above all, in order to explore the safety risk of TCM, there is
great necessity of toxicology research in drug safety evaluation of
TCM.
DEFICIENCIES OF STANDARD ANIMAL MODEL AND
NECESSITIES OF MORBID ANIMAL MODEL IN DRUG
SAFETY EVALUATION
To evaluate drug safety, there are several deficiencies in current
standard animal models, and we should pay more attention to
morbid animal models.
NEED FOR DISEASE ANIMAL MODELS
As is known, the drug is usually used in patients with a morbid
status. The ultimate goal of drug safety evaluation is to reduce
the safety risk of clinical medication, rather than experimental
animals. So there are some deficiencies to predict the safety of
drugs in patients with the data generated from normal animals.
Adverse reactions might happen in normal animals, but might
not occur in patients with the morbid status; and vice versa.
What’s more, the exposure of drug in humans cannot solve each
problem. Usually we can predict some changes of toxicity in
humans with the changes of exposure. But the same exposure may
bring different toxicity in humans in different healthy statuses.
This different presentation of toxicity may be brought by the
different cellular function or different receptor level in healthy
people or patients. So in order to predict the clinical toxicity
of drugs more accurately, can we evaluate with morbid animal
model?
In the theory of TCM, the difference of drug safety revealed
in healthy and morbid subjects has been already recognized. The
abstruse theory—“You Gu Wu Yun” ( ) means that if a
pregnant woman has an abdominal mass, the violent medicine
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will suit the disease status, both the mother and the fetus will
be unharmed. That means, a drug will reveal its therapeutic
target when it is prescribed to patients with the right indications,
while it may produce deleterious effects in both sick and healthy
people as a result of incorrect indications. For example, the
blood-activation Chinese medicine can induce miscarriage, but
for pregnant women of blood stasis syndrome, it will be less risky.
NEED FOR CLINICAL TRIALS
Because of the different presentations of toxicity in healthy people
or patients, the risk for drugs administrated to patients will
increase with the absence of safety data from morbid subjects,
including animals or humans. Suppose a drug has not been
observed hepatotoxicity in normal animals, it can still cause
irreversible liver injury or serious adverse events while being used
in patients with decreased liver function or combined with a
certain drug with hepatotoxicity.
What’s more, for some special indications, such as tumors,
drugs with severe toxicity should not be tested in healthy vol-
unteers with the perspective of ethics. Under this circumstance,
patients are often directly used in Phase I clinical trials. Then
patients will take a greater risk because of the absence of safety
data from the morbid animals as a reference.
LITERATURE SUPPORTS FOR DISEASE ANIMAL MODELS
There are limitations in predicting drug clinical risk merely by
standard animal data. Olson et al. (2000) investigation of the
multinational pharmaceutical companies showed that the non-
clinical safety study using both rodents and non-rodents can
only achieve 71% of consistent prediction with clinically occurred
toxicity; while tests only using non-rodents or rodents can achieve
63 or 43% of consistency, respectively. In addition to the species
differences between animals and humans, the difference of patho-
logical /physiological statuses may also contribute, at least in part,
to the inconsistency.
Some scholars compared toxicity of the same drug between
the morbid models and normal animals. Wang et al. (2011)
compared toxic effects of rhubarb (with main components that
can cause liver damage such as emodin and rhein), a common
TCM for treatment of hepatitis, between normal rats and CCl4
hepatic injury model rats. Wang found that toxic tolerance of
CCl4hepatic injury model rats against rhubarb was higher than
normal animals. Fang et al. (2011) discovered that concentrations
of rhein, emodin and aloe emodin (the main toxic compo-
nent) in the liver, kidney, spleen of the liver-injured rats was
significantly lower than those of normal animals after taken
rhubarb extraction orally for 12 weeks. Jiang et al. (2012) found
that there were obvious differences in t1/2, AUC0−t, AUC0−∞,
Tmax, and CLz/F of paeoniflorin and albiflorin between the
normal rats and α-isothiocyanate naphthalene ester (ANIT)
induced acute cholestasis hepatitis model rats taken red paeony
root, and pharmacokinetics process could be changed in rats
with acute liver injury. Based on the above data, drug toxic-
ity and pharmacokinetic process between morbid animals and
normal animals tend to be different, which further prompts
that adopting the morbid animal model is necessary to safety
evaluation.
CONSIDERATION ON THE MORBID ANIMAL MODEL IN TCM
STUDY
Due to the particularity of TCM and the deficiencies of standard
animal model in drug safety evaluation, it is necessary to evaluate
the non-clinical safety of TCM new drugs by a combination
strategy of the standard toxicology model and the morbid animal
model.
There are several good reasons. Firstly, the compositions of
TCMs are complex and their toxic ingredients are often unclear.
Therefore, targeted pharmacokinetic study (ADME/T) cannot be
conducted easily, which restricts bridging studies of the safety data
from the health status to the pathological status. Secondly, the
ADME study of TCM is usually comparatively weak, so that it is
difficult to predict the safety of TCM in patients with ADME data.
Thirdly, there are deficiencies of standard animal models in drug
safety evaluation. So sometimes we need to consider the use of
morbid animal models in safety study of TCM.
RELATED CONTENT IN GUIDELINES
Although there is no specific guideline using morbid animal
models in non-clinical drug safety evaluation, some guiding
principles have referred to this in International Conference on
Harmonization (ICH).
In ICH, 2011, it has been pointed out that the alternative study
by using animal models similar to human disease could be used in
drug safety evaluation: these animal models include spontaneous
or induced animal models of disease, gene knockout and trans-
genic animals. These models may provide further insight, not
only in determining the pharmacological action of the product,
pharmacokinetics, and dosimetry, but may also be useful in the
determination of safety (e.g., evaluation of undesirable promo-
tion of disease progression). In certain cases, studies performed
in animal models of disease may be used as acceptable alternative
models to toxicity studies in normal animals.
Although such models are referred to biological drugs in ICH
S6, universal significance should be considered to all kinds of
drugs including TCM.
In ICH, 2005, it has also been mentioned that animal models
might have utility in assessing proarrhythmia of drugs.
In ICH, 2009, the application of the morbid animal model
was not mentioned in non-clinical safety evaluation of anticancer
drugs. But in order to predict the safety of the drug in cancer
patients more accurately, there are still a part of applicants who
adopted tumor-burdened animals for non-clinical safety evalu-
ation in the development of anti-cancer drugs (Ferreira et al.,
2012).
PERSPECTIVE
In recent years, researches on disease mechanism, basic sciences
and morbid animal models have progressed rapidly. That made it
easier for us to study the safety of drugs with morbid animals.
On the other hand, as with standard animal models, adopting
morbid animal models also has limitations in predicting drug
safety to the patients. Due to the short development time and
limited basic research, adopting morbid animal models in non-
clinical safety study may face certain challenges such as lim-
ited historical background data and difficulties in interpreting
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study data. So it is essential to collect control data and base-
line data in the same period in order to draw more scientific
conclusions.
In spite of some deficiencies, in order to predict the clinical
toxicity of drugs as accurately as possible and reduce the risks to
clinical subjects, it is necessary to pay more attention to the use
of morbid animals in pre-clinical safety research. Because of the
characteristics of TCM, safety studies should also be considered in
research and development of new drugs of TCM, and sometimes
using morbid animal models could be a good choice. For some
new drugs that include high risk Chinese medicines (e.g., that
with narrow safety margin, severe toxicity, steep dose-response,
prone to accumulation, etc.), or other conditions that using
for high-risk groups or health factors that may influence drug
reaction, morbid animal models could be used as the necessity
for non-clinical safety evaluation.
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